Suppliers / Sterling Wisconsin

Sterling Wisconsin

United States Updated 9 July 2026

Sterling Wisconsin is an API manufacturer based in United States. It holds 5 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 12 March 2024 as NAI.

5
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 12 March 2024 NAI US FDA
  • 24 June 2016 NAI US FDA
  • 18 September 2013 VAI US FDA
  • 16 December 2011 VAI US FDA
  • 4 August 2009 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Germantown, United States 3004485164

What they file, and where

Molecule Regulators Docs
Dexmedetomidine US FDA 1
Dexrazoxane US FDA 1
Isoprenaline US FDA 1
Isradipine US FDA 1
Midodrine US FDA 1

Also appears on these molecule pages

Dexmedetomidine API Dexrazoxane API Isoprenaline API Isradipine API Midodrine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Sterling Wisconsin comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 12 March 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates